GenMont Biotech Inc (3164) - Total Liabilities
Based on the latest financial reports, GenMont Biotech Inc (3164) has total liabilities worth NT$185.54 Million TWD (≈ $5.85 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore 3164 operating cash flow to assess how effectively this company generates cash.
GenMont Biotech Inc - Total Liabilities Trend (2003–2024)
This chart illustrates how GenMont Biotech Inc's total liabilities have evolved over time, based on quarterly financial data. Check GenMont Biotech Inc liquid asset ratio to evaluate the company's liquid asset resilience ratio.
GenMont Biotech Inc Competitors by Total Liabilities
The table below lists competitors of GenMont Biotech Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Korea Refract
KO:010040
|
Korea | ₩110.26 Billion |
|
SRG HOUSING FINANCE ORD (BSE)
NSE:SRGHFL
|
India | Rs7.04 Billion |
|
Findi Ltd
AU:FND
|
Australia | AU$257.71 Million |
|
IT City Public Company Limited
BK:IT
|
Thailand | ฿2.62 Billion |
|
Energia Latina SA
SN:ENLASA
|
Chile | CL$56.58 Million |
|
NOMADAR Corp. Class A Common Stock
NASDAQ:NOMA
|
USA | $5.11 Million |
|
IBKS No. 15 Special Purpose Acquisition Co. Ltd.
KQ:373200
|
Korea | ₩46.29 Billion |
|
Ewein Bhd
KLSE:7249
|
Malaysia | RM200.30 Million |
Liability Composition Analysis (2003–2024)
This chart breaks down GenMont Biotech Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see 3164 company net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.82 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.15 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.12 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how GenMont Biotech Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for GenMont Biotech Inc (2003–2024)
The table below shows the annual total liabilities of GenMont Biotech Inc from 2003 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | NT$229.06 Million ≈ $7.22 Million |
+12.25% |
| 2023-12-31 | NT$204.06 Million ≈ $6.43 Million |
+2.75% |
| 2022-12-31 | NT$198.59 Million ≈ $6.26 Million |
+14.36% |
| 2021-12-31 | NT$173.65 Million ≈ $5.47 Million |
+32.61% |
| 2020-12-31 | NT$130.95 Million ≈ $4.13 Million |
+6.43% |
| 2019-12-31 | NT$123.04 Million ≈ $3.88 Million |
+28.70% |
| 2018-12-31 | NT$95.60 Million ≈ $3.01 Million |
-26.13% |
| 2017-12-31 | NT$129.41 Million ≈ $4.08 Million |
+4.25% |
| 2016-12-31 | NT$124.14 Million ≈ $3.91 Million |
-6.96% |
| 2015-12-31 | NT$133.43 Million ≈ $4.20 Million |
-7.82% |
| 2014-12-31 | NT$144.76 Million ≈ $4.56 Million |
-73.02% |
| 2013-12-31 | NT$536.49 Million ≈ $16.90 Million |
-5.32% |
| 2012-12-31 | NT$566.61 Million ≈ $17.85 Million |
-3.65% |
| 2011-12-31 | NT$588.06 Million ≈ $18.53 Million |
-6.31% |
| 2010-12-31 | NT$627.66 Million ≈ $19.77 Million |
+609.88% |
| 2009-12-31 | NT$88.42 Million ≈ $2.79 Million |
+23.90% |
| 2008-12-31 | NT$71.36 Million ≈ $2.25 Million |
+51.70% |
| 2007-12-31 | NT$47.04 Million ≈ $1.48 Million |
-20.52% |
| 2006-12-31 | NT$59.18 Million ≈ $1.86 Million |
+152.80% |
| 2005-12-31 | NT$23.41 Million ≈ $737.54K |
+56.97% |
| 2004-12-31 | NT$14.91 Million ≈ $469.87K |
+54.95% |
| 2003-12-31 | NT$9.62 Million ≈ $303.24K |
-- |
About GenMont Biotech Inc
GenMont Biotech Incorporation engages in the research and development, manufacture, and sale of various probiotic health products in Taiwan. It offers OEM and ODM services, including functional probiotic raw materials, capsules, powder, tablets, and liquid products. The company was founded in 2000 and is based in Tainan City, Taiwan.